Allergan agrees to pay $300m to end birth control litigation

Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Supermarket chain settles pay-for-delay suit over birth control pill

19 December 2019 Dutch supermarket owner Ahold Delhaize has agreed to settle a series of patent infringement suits filed against pharmaceutical companies including Warner Chilcott and Watson over contraceptive pill Loestrin 24 Fe.

Americas

Allergan pays $750m to resolve antitrust litigation

29 October 2019 Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

Americas

Apollo’s Covis sues over preterm-birth drug patents

5 January 2021 Aurobindo’s subsidiary Eugia allegedly infringed two patents for an injectable treatment for reducing the risk of premature birth, according to a lawsuit by Covis Pharma, a Luxembourg-based unit of Apollo Global Management.

More on this story

Americas

Supermarket chain settles pay-for-delay suit over birth control pill

Americas

Allergan pays $750m to resolve antitrust litigation

29 October 2019 Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

Americas

Apollo’s Covis sues over preterm-birth drug patents

More on this story

Americas

Supermarket chain settles pay-for-delay suit over birth control pill

Americas

Allergan pays $750m to resolve antitrust litigation

29 October 2019 Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

Americas

Apollo’s Covis sues over preterm-birth drug patents